Claire Verschraegen to lead medical oncology division at Ohio State

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Claire Verschraegen was appointed director of the Division of Medical Oncology and associate director of the Translational Research Program at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Verschraegen also holds the Diane Nye and Michael Rayden Chair in Innovative Cancer Research and serves as...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login